Cargando…

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series

Objectives: Cannabidiol (CBD) is a non-psychotomimetic cannabinoid compound that is found in plants of the genus Cannabis. Preclinical research has suggested that CBD may have a beneficial effect in rodent models of post-traumatic stress disorder (PTSD). This effect is believed to be due to the acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Elms, Lucas, Shannon, Scott, Hughes, Shannon, Lewis, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482919/
https://www.ncbi.nlm.nih.gov/pubmed/30543451
http://dx.doi.org/10.1089/acm.2018.0437
_version_ 1783413968500424704
author Elms, Lucas
Shannon, Scott
Hughes, Shannon
Lewis, Nicole
author_facet Elms, Lucas
Shannon, Scott
Hughes, Shannon
Lewis, Nicole
author_sort Elms, Lucas
collection PubMed
description Objectives: Cannabidiol (CBD) is a non-psychotomimetic cannabinoid compound that is found in plants of the genus Cannabis. Preclinical research has suggested that CBD may have a beneficial effect in rodent models of post-traumatic stress disorder (PTSD). This effect is believed to be due to the action of CBD on the endocannabinoid system. CBD has seen a recent surge in research regarding its potential value in a number of neuro-psychiatric conditions. This is the first study to date examining the clinical benefit of CBD for patients with PTSD. Methods: This retrospective case series examines the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic. CBD was given on an open-label, flexible dosing regimen to patients diagnosed with PTSD by a mental health professional. Patients also received routine psychiatric care, including concurrent treatment with psychiatric medications and psychotherapy. The length of the study was 8 weeks. PTSD symptom severity was assessed every 4 weeks by patient-completed PTSD Checklist for the DSM-5 (PCL-5) questionnaires. Results: From the total sample of 11 patients, 91% (n = 10) experienced a decrease in PTSD symptom severity, as evidenced by a lower PCL-5 score at 8 weeks than at their initial baseline. The mean total PCL-5 score decreased 28%, from a mean baseline score of 51.82 down to 37.14, after eight consecutive weeks of treatment with CBD. CBD was generally well tolerated, and no patients discontinued treatment due to side effects. Conclusions: Administration of oral CBD in addition to routine psychiatric care was associated with PTSD symptom reduction in adults with PTSD. CBD also appeared to offer relief in a subset of patients who reported frequent nightmares as a symptom of their PTSD. Additional clinical investigation, including double-blind, placebo-controlled trials, would be necessary to further substantiate the response to CBD that was observed in this study.
format Online
Article
Text
id pubmed-6482919
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-64829192019-04-26 Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series Elms, Lucas Shannon, Scott Hughes, Shannon Lewis, Nicole J Altern Complement Med Original Articles Objectives: Cannabidiol (CBD) is a non-psychotomimetic cannabinoid compound that is found in plants of the genus Cannabis. Preclinical research has suggested that CBD may have a beneficial effect in rodent models of post-traumatic stress disorder (PTSD). This effect is believed to be due to the action of CBD on the endocannabinoid system. CBD has seen a recent surge in research regarding its potential value in a number of neuro-psychiatric conditions. This is the first study to date examining the clinical benefit of CBD for patients with PTSD. Methods: This retrospective case series examines the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic. CBD was given on an open-label, flexible dosing regimen to patients diagnosed with PTSD by a mental health professional. Patients also received routine psychiatric care, including concurrent treatment with psychiatric medications and psychotherapy. The length of the study was 8 weeks. PTSD symptom severity was assessed every 4 weeks by patient-completed PTSD Checklist for the DSM-5 (PCL-5) questionnaires. Results: From the total sample of 11 patients, 91% (n = 10) experienced a decrease in PTSD symptom severity, as evidenced by a lower PCL-5 score at 8 weeks than at their initial baseline. The mean total PCL-5 score decreased 28%, from a mean baseline score of 51.82 down to 37.14, after eight consecutive weeks of treatment with CBD. CBD was generally well tolerated, and no patients discontinued treatment due to side effects. Conclusions: Administration of oral CBD in addition to routine psychiatric care was associated with PTSD symptom reduction in adults with PTSD. CBD also appeared to offer relief in a subset of patients who reported frequent nightmares as a symptom of their PTSD. Additional clinical investigation, including double-blind, placebo-controlled trials, would be necessary to further substantiate the response to CBD that was observed in this study. Mary Ann Liebert, Inc., publishers 2019-04-01 2019-04-09 /pmc/articles/PMC6482919/ /pubmed/30543451 http://dx.doi.org/10.1089/acm.2018.0437 Text en © Lucas Elms et al, 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
spellingShingle Original Articles
Elms, Lucas
Shannon, Scott
Hughes, Shannon
Lewis, Nicole
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
title Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
title_full Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
title_fullStr Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
title_full_unstemmed Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
title_short Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
title_sort cannabidiol in the treatment of post-traumatic stress disorder: a case series
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482919/
https://www.ncbi.nlm.nih.gov/pubmed/30543451
http://dx.doi.org/10.1089/acm.2018.0437
work_keys_str_mv AT elmslucas cannabidiolinthetreatmentofposttraumaticstressdisorderacaseseries
AT shannonscott cannabidiolinthetreatmentofposttraumaticstressdisorderacaseseries
AT hughesshannon cannabidiolinthetreatmentofposttraumaticstressdisorderacaseseries
AT lewisnicole cannabidiolinthetreatmentofposttraumaticstressdisorderacaseseries